Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1986-11-21
|
pubmed:abstractText |
The effects of radiation therapy and adjuvant chemoimmunotherapy on the immune competence of patients with breast cancer were investigated. The tests performed included intradermal tuberculin tests, T- and B-lymphocyte counts, and lymphocyte blast transformation tests; phytohemagglutinin (PHA), concanavalin A (ConA) and pokeweed mitogen (PWM) were used as mitogens. Enhancement in lymphocyte proliferative response to mitogenic stimulation by PHA and PWM was seen in patients after 3 courses of chemotherapy + levamisole, whereas irradiation given after chemotherapy caused long-lasting depression in response to PHA (p = 0.039) and PWM (not significant). T-lymphocyte counts were also lower after irradiation than after chemoimmunotherapy (p = 0.007). Clinically, the 16 patients treated with radiation therapy after chemotherapy exhibited a higher recurrence rate than the 24 patients treated first by irradiation. Enhanced reactivity to tuberculin tests occurred generally in patients receiving a planned treatment including irradiation, chemotherapy (5-fluorouracil, doxorubicin, cyclophosphamide) and levamisole. Enhancement of reactivity was seen more often in patients who had not relapsed.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cobalt Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Levamisole
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0349-652X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
161-6
|
pubmed:dateRevised |
2006-12-5
|
pubmed:meshHeading |
pubmed-meshheading:3020878-Adult,
pubmed-meshheading:3020878-Aged,
pubmed-meshheading:3020878-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3020878-Breast Neoplasms,
pubmed-meshheading:3020878-Cobalt Radioisotopes,
pubmed-meshheading:3020878-Combined Modality Therapy,
pubmed-meshheading:3020878-Cyclophosphamide,
pubmed-meshheading:3020878-Doxorubicin,
pubmed-meshheading:3020878-Female,
pubmed-meshheading:3020878-Fluorouracil,
pubmed-meshheading:3020878-Humans,
pubmed-meshheading:3020878-Immunocompetence,
pubmed-meshheading:3020878-Levamisole,
pubmed-meshheading:3020878-Mastectomy,
pubmed-meshheading:3020878-Middle Aged,
pubmed-meshheading:3020878-Postoperative Care,
pubmed-meshheading:3020878-Radioisotope Teletherapy,
pubmed-meshheading:3020878-Time Factors
|
pubmed:articleTitle |
Postoperative radiation therapy and adjuvant chemoimmunotherapy in breast cancer. Aspects of timing and immune competence.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|